Singapore still falling short for home-grown biotechs seeking IPO
Tough SGX mainboard listing rules, low liquidity, lack of deep institutional investor pool and sparse research ecosystem among reasons cited
Add BT as a preferred source
Singapore
HOME-GROWN biotech companies would rather look for opportunities further ashore than list on the Singapore Exchange (SGX). Although the city-state has a growing biotech ecosystem, the local bourse has not been able to benefit much from it.
Industry players who spoke to The Business Times brought up issues of low liquidity, the lack of a deep institutional investor pool and a sparse research ecosystem as reasons why they would look elsewhere.
TRENDING NOW
Singapore developer in limbo after Timor-Leste scraps major township project
Troubled platform UCars founded by group of dealers wound up on S$4 million debt
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
That ‘cheap’ Malaysia condo could cost Singapore buyers far more than they think
